Gossamer Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GOSS Nasdaq 2836 www.gossamerbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gossamer Bio, Inc.

Gossamer Bio (GOSS) Q1 2026 Earnings Transcript - May 27th, 2026 2:17 pm
Pulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsight - May 25th, 2026 3:31 pm
Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS) - May 18th, 2026 8:14 am
Gossamer Bio Q1 Earnings Call Highlights - May 18th, 2026 7:05 am
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support - May 18th, 2026 5:05 am
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update - May 18th, 2026 5:00 am
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - May 15th, 2026 5:30 pm
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 - May 15th, 2026 5:01 am
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates - May 14th, 2026 6:30 am
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2026 3:15 pm
How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash Concerns - May 11th, 2026 2:14 pm
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates - May 11th, 2026 6:40 am
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates - May 7th, 2026 5:05 pm
How Mixed Trial Results And Balance Sheet Pressure Are Reframing The Gossamer Bio (GOSS) Story - Apr 23rd, 2026 12:05 am
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Apr 12th, 2026 3:47 pm
Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral - Apr 7th, 2026 8:30 am
Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback - Mar 30th, 2026 12:23 am
Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue - Mar 24th, 2026 3:46 pm
Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory Environment - Mar 20th, 2026 1:16 pm
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates - Mar 17th, 2026 3:10 pm